Form 4: Director Jasinski Reports Dividend Equivalent Rights Accrual

Lemaitre Vascular Director Lawrence J. Jasinski reported the accrual of dividend equivalent rights tied to his restricted and performance stock unit awards.

Summary

• Director Lawrence J. Jasinski reported the accrual of dividend equivalent rights (DERs) on March 26, 2026.
• These DERs are tied to previously granted restricted stock unit (RSU) and performance share unit (PSU) awards.
• A total of 3.444 DERs were accrued across five different awards on this date.
• Each dividend equivalent right is the economic equivalent of one share of Lemaitre Vascular Inc. common stock and vests proportionately with the underlying awards.
• Following these accruals, Jasinski's beneficial ownership of DERs for specific awards stands at 4.6016, 4.3113, 3.5389, 3.6239, and 1.2077, respectively.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive routine filing, reflecting ongoing executive compensation and alignment of director interests with shareholders through equity awards.

Positives

• Accrual of dividend equivalent rights indicates ongoing participation in company performance and aligns director interests with shareholders.
• The vesting of these rights is tied to existing RSU and PSU awards, suggesting continued long-term commitment from the director.

Future Outlook

This Form 4 does not contain forward-looking statements or guidance beyond the vesting schedule of the underlying awards, which will vest proportionately with their respective restricted stock unit and performance share unit awards.

Industry Context

StockSavvy.ai notes that the accrual of dividend equivalent rights is a standard component of executive and director compensation packages, particularly for equity awards like RSUs and PSUs. This practice aims to ensure that award holders receive the economic benefit of dividends, aligning their interests with common shareholders even before the underlying shares fully vest.

Comparison to Industry Standards

• The use of dividend equivalent rights tied to restricted and performance stock units is a common practice in executive compensation across various industries, including medical devices.
• Companies like Medtronic (MDT) and Boston Scientific (BSX) also utilize similar equity-based compensation structures for their executives and directors, often including provisions for dividend equivalents to maintain alignment with shareholder returns.
• The specific fractional amounts of DERs reflect the pro-rata accrual based on the underlying share awards and dividend payouts, which is consistent with typical compensation plan mechanics.

Stakeholder Impact

• Shareholders: The accrual of dividend equivalent rights aligns the director's financial interests with those of common shareholders, as the value of these rights is tied to the company's common stock and its dividend policy.

Next Steps

• The dividend equivalent rights will vest proportionately with their respective underlying restricted stock unit and performance share unit awards.

Key Dates

Recommendation

This Form 4 filing details a routine accrual of dividend equivalent rights for a director, which is part of an established compensation plan. It does not indicate any new strategic developments, financial performance changes, or significant shifts in insider sentiment that would warrant a change in investment recommendation. The transaction is neutral in its implications for the company's fundamental value or future prospects, thus a 'hold' recommendation is appropriate.

Keywords

Lemaitre Vascular, LMAT, Form 4, Insider Transaction, Dividend Equivalent Rights, Restricted Stock Units, Performance Share Units, Executive Compensation, Director Ownership